04:09 AM EST, 02/13/2025 (MT Newswires) -- Ascendis Pharma ( ASND ) said late Wednesday its board has allocated $25 million to fund a share buyback program and the net settlement of certain restricted stock units, or RSUs.

The buyback program authorizes the repurchase from time to time of up to about $18.3 million of American depositary shares.

The company also plans to apply a net settlement of tax-withholding obligations related to certain RSUs for about $9 million in cash.